Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Dan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7789-6747; OpenAlex author ID A5115596117. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae207↗
  2. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian rando… Co-author DOI 10.1016/j.lanwpc.2022.100596↗
  3. Transparency of clinical trials in pancreatic cancer: An analysis of availability of trial results from the ClinicalTrials.gov database. Co-author DOI 10.3389/fonc.2022.1026268↗
  4. The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision. Co-author DOI 10.7150/jca.64800↗
  5. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1111/ajco.13504↗
  6. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.4143/crt.2020.330↗
  7. A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. Co-author DOI 10.7150/jca.57768↗
  8. Preoperative Mean Corpuscular Hemoglobin Concentration, Red Cell Distribution Width As Predictive Markers For Pancreatic Cancer Patients Who Underwent Radical … Co-author DOI 10.21203/rs.3.rs-37763/v1↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaona Fan · 2 shared papers, 2020–2024 · strength 0.27
  2. Changjie Lou · 2 shared papers, 2021–2024 · strength 0.27
  3. Zhiwei Li · 2 shared papers, 2021–2024 · strength 0.27
  4. Yanqiao Zhang · 2 shared papers, 2021–2024 · strength 0.27
  5. Yuqiang Li · 2 shared papers, 2021–2022 · strength 0.27
  6. Cenap Güngör · 2 shared papers, 2021–2022 · strength 0.27
  7. Lin Fang · 2 shared papers, 2020–2021 · strength 0.22
  8. Liang‐Hao Hu · 1 shared paper, 2022 · strength 0.17
  9. Zhaoshen Li · 1 shared paper, 2022 · strength 0.17
  10. Ren-Qian Huang · 1 shared paper, 2022 · strength 0.17
  11. Hengzhen Li · 1 shared paper, 2024 · strength 0.16
  12. Tongsen Zheng · 1 shared paper, 2024 · strength 0.16
  13. Biaoxiang Xu · 1 shared paper, 2022 · strength 0.15
  14. Zhongyi Zhou · 1 shared paper, 2022 · strength 0.15
  15. Xiongxiong Lu · 1 shared paper, 2023 · strength 0.14
  16. Yan Shi · 1 shared paper, 2023 · strength 0.14
  17. Chenlei Wen · 1 shared paper, 2023 · strength 0.14
  18. Baiyong Shen · 1 shared paper, 2023 · strength 0.14
  19. Pengxian Tao · 1 shared paper, 2021 · strength 0.12
  20. Yang Yu · 1 shared paper, 2021 · strength 0.12
  21. Christine Nitschke · 1 shared paper, 2021 · strength 0.12
  22. Hao Chen · 1 shared paper, 2021 · strength 0.12
  23. Zhiwei Li · 1 shared paper, 2020 · strength 0.11
  24. Yang Yao · 1 shared paper, 2021 · strength 0.11
  25. Jie Lian · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.